Experimental eye injection aims to slow vision loss from geographic atrophy

NCT ID NCT07230834

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 25, 2026 · Updated 27 times

Summary

This early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA), a condition that damages the retina and causes vision loss. The main goal is to check the drug's safety and tolerability in 54 participants. Researchers will also measure how much drug stays in the body and whether the immune system reacts to it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Retina Associates
RECRUITING

Austin, Texas, 78705, United States
Colorado Retina Associates
RECRUITING

Lakewood, Colorado, 80228, United States
Ophthalmic Consultants of Boston
RECRUITING

East Weymouth, Massachusetts, 02189, United States
Retina Consultants Texas
RECRUITING

The Woodlands, Texas, 77384, United States
Retina Foundation of the Southwest
RECRUITING

Dallas, Texas, 75231, United States

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY (GA)